Evidence map›Paper›PMID 26415561›Full record

ArticleScientific reports2015

On/off-switchable anti-neoplastic nanoarchitecture.

Hirak K Patra, Roghayeh Imani, Jaganmohan R Jangamreddy, Meysam Pazoki, Aleš Iglič, Anthony P F Turner, Ashutosh Tiwari

Abstract read
In one paragraph

Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hirak K PatraBiosensors and Bioelectronics Centre, IFM, Linköping University, 58183, Linköping, Sweden.
Roghayeh ImaniBiosensors and Bioelectronics Centre, IFM, Linköping University, 58183, Linköping, Sweden.
Jaganmohan R JangamreddyDivision of Cell Biology, Department of Clinical and Experimental Medicine (IKE), Linköping University, 58185 Linköping, Sweden.
Meysam PazokiDepartment of Chemistry, Ångström Laboratory, Uppsala University, Lägerhyddsvägen 1, 75120 Upssala, Sweden.
Aleš IgličLaboratory of Biophysics, Faculty of Electrical Engineering, University of Ljubljana, SI-1000 Ljubljana, Slovenia.
Anthony P F TurnerBiosensors and Bioelectronics Centre, IFM, Linköping University, 58183, Linköping, Sweden.
Ashutosh TiwariBiosensors and Bioelectronics Centre, IFM, Linköping University, 58183, Linköping, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Throughout the world, there are increasing demands for alternate approaches to advanced cancer therapeutics. Numerous potentially chemotherapeutic compounds are developed every year for clinical trial and some of them are considered as potential drug candidates. Nanotechnology-based approaches have accelerated the discovery process, but the key challenge still remains to develop therapeutically viable and physiologically safe materials suitable for cancer therapy. Here, we report a high turnover, on/off-switchable functionally popping reactive oxygen species (ROS) generator using a smart mesoporous titanium dioxide popcorn (TiO2 Pops) nanoarchitecture. The resulting TiO2 Pops, unlike TiO2 nanoparticles (TiO2 NPs), are exceptionally biocompatible with normal cells. Under identical conditions, TiO2 Pops show very high photocatalytic activity compared to TiO2 NPs. Upon on/off-switchable photo activation, the TiO2 Pops can trigger the generation of high-turnover flash ROS and can deliver their potential anticancer effect by enhancing the intracellular ROS level until it crosses the threshold to open the 'death gate', thus reducing the survival of cancer cells by at least six times in comparison with TiO2 NPs without affecting the normal cells.

Indexed as

Antineoplastic AgentsCell LineCell Line, TumorCell SurvivalFibroblastsHEK293 CellsHumansLightMetal NanoparticlesOrgan SpecificityOxidative StressPhotochemical ProcessesReactive Oxygen SpeciesTitaniumAntineoplastic AgentsReactive Oxygen SpeciesTitaniumtitanium dioxide

Identifiers

PMID26415561
PMCPMC4586894

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.